



**FERMENTA BIOTECH GMBH
FINANCIAL STATEMENTS
FOR THE YEAR ENDED
31ST MARCH, 2021**

Standalone Balance Sheet as at March 31, 2021


(' in EUR)

	Notes	March 31, 2021	March 31, 2020
ASSETS			
Non-current assets			
Other Intangible assets	1	464.573,70	560.417,70
Total non-current assets		464.573,70	560.417,70
Current assets			
(a) Inventories	2	3.395.019,00	2.046.673,83
(b) Financial assets			
(i) Trade receivables	3	15.280,00	106.312,50
(ii) Cash and cash equivalents	4	5.004,15	41.293,86
(c) Other current assets	5	143.242,21	1.293,66
Total current assets		3.558.545,36	2.195.573,85
TOTAL ASSETS		4.023.119,06	2.755.991,55
EQUITY AND LIABILITIES			
Equity			
(a) Equity share capital	6	25.000,00	25.000,00
(b) Other equity	7	(497.413,40)	(277.426,45)
Total equity		(472.413,40)	(252.426,45)
Liabilities			
Current liabilities			
(a) Financial liabilities			
(iii) Trade payables			
Total outstanding dues of creditors other than micro and small enterprises	8	4.481.854,58	3.008.418,00
(b) Current tax liabilities (net)	9	13.677,88	-
Total current liabilities		4.495.532,46	3.008.418,00
TOTAL EQUITY AND LIABILITIES		4.023.119,06	2.755.991,55

See accompanying notes to the Standalone financial statements

1-18

In terms of our report attached

For
Chartered Accountants

Thomas Burmester
PartnerDate : 16th June, 2021
Place : HamburgFor and on behalf of the Board of Directors of
Fermenta Biotech GmbH

Viviane Spethmann- Berssenbrügge
Managing DirectorDate : 16th June, 2021
Place : Hamburg

Standalone Statement of Profit and Loss for the year ended March 31, 2021

(` in EUR)

	Notes	'March 31, 2021	March 31, 2020
Income			
Revenue from operations	10	245.910,00	106.312,50
Other income	11	184.621,88	-
Total income		430.531,88	106.312,50
Expenses			
Cost of materials consumed	12	1.274.122,73	1.136.468,00
Purchases of stock-in-trade		-	-
Changes in inventories of finished goods, stock-in-trade and work-in-progress	13	(1.145.248,48)	(790.368,67)
Employee benefits expense		-	-
Finance costs		-	-
Depreciation and amortisation expense	14	119.029,00	-
Other expenses	15	402.615,58	37.639,62
Total expenses		650.518,83	383.738,95
Profit before tax		(219.986,95)	(277.426,45)
Tax expense:			
Current tax		-	-
Deferred tax credit		-	-
Total tax expense		-	-
Profit for the year		(219.986,95)	(277.426,45)
Other comprehensive income			
Total other comprehensive income / (loss) for the year (a+b)		-	-
Total comprehensive income for the year		(219.986,95)	(277.426,45)
Earnings per equity share of ` 1 each EUR			
Basic in EUR		(8,80)	(11,10)
See accompanying notes to the Standalone financial statements		1-18	
In terms of our report attached			

For
Chartered Accountants



Thomas Burmester
Partner

Date : 16th June, 2021
Place : Hamburg

For and on behalf of the Board of Directors of
Fermenta Biotech GmbH



Viviane Spethmann- Berssenbrügge
Managing Director

Date : 16th June, 2021
Place : Hamburg

(' in EUR)

1-18

**For and on behalf of the Board of Directors of
Fermenta Biotech GmbH**

Viviane Speßhmann- Berssenbrügge
Managing Director

Date : 16th June, 2021
Place : Hamburg

Standalone Statement of Changes in Equity for the year ended March 31, 2021

(a) Equity share capital

(' in EUR)

	March 31, 2021	March 31, 2020
Balance at the beginning of the year	25.000,00	25.000,00
Balance at the end of the year	25.000,00	25.000,00


(b) Other equity

	Reserves and Surplus							Items of other comprehensive income	Total
	Unrealised gain/(loss) on dilution	Capital redemption reserve	Capital reserve pursuant to amalgamation	Capital reserve	General reserve	Share options outstanding account	Retained earnings	Equity instruments through OCI	
Balance as at March 31, 2019	-	-	-	-	-	-	-	-	-
Profit for the year	-	-	-	-	-	-	(277.426,45)	-	(277.426,45)
Balance as at March 31, 2020	-	-	-	-	-	-	(277.426,45)	-	(277.426,45)
Profit for the year	-	-	-	-	-	-	(219.986,95)	-	(219.986,95)
Balance as at March 31, 2021	-	-	-	-	-	-	(497.413,40)	-	(497.413,40)

In terms of our report attached

For
Chartered Accountants


Thomas Burmester
Partner

Date : 16th June, 2021
Place : HamburgFor and on behalf of the Board of Directors of
Fermenta Biotech GmbH


Viviane Spethmann-Berssenbrügge
Managing Director

Date : 16th June, 2021
Place : Hamburg

Standalone Cash Flow Statement for the year ended March 31, 2021

(' in EUR)


	March 31, 2021	March 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES		
Profit before tax	(219.986,95)	(277.426,45)
Adjustments for :		
Depreciation and amortisation expense	119.029,00	-
Liabilities / provisions no longer required written back	(184.621,88)	-
Operating profit before working capital changes	(285.579,83)	(277.426,45)
Movements in working capital:		
(Increase)/decrease in trade receivables	91.032,50	(106.312,50)
Increase in inventories	(1.348.345,44)	(2.046.673,83)
(Increase)/decrease in other assets	(141.948,55)	(1.293,66)
Increase in trade payables	1.473.436,64	3.008.418,00
Increase in provisions	184.621,88	-
Increase / (decrease) in other liabilities	13.677,88	-
	(13.104,92)	576.711,56
Income taxes paid (net of refunds)	-	-
Net cash generated from operation (A)	(13.104,92)	576.711,56
CASH FLOWS FROM INVESTING ACTIVITIES		
Payments for purchase of property, plant and equipment, investment property, capital work-in-progress, intangible assets and intangible assets under development	(23.185,00)	(560.417,70)
Proceeds on sale of property, plant and equipment	-	25.000,00
Net cash used in investing activities (B)	(23.185,00)	(535.417,70)
CASH FLOWS FROM FINANCING ACTIVITIES		
Net cash generated from / (used in) financing activities (C)	-	-
Net increase / (decrease) in cash and cash equivalents (A)+(B)+(C)	(36.289,92)	41.293,86
Cash and cash equivalents at the beginning of the year	41.293,86	-
Cash and cash equivalents at the end of the year	5.004,15	41.293,86
Components of cash and cash equivalents		
Cash on hand	-	-
Balances with banks:		
In current accounts	5.004,15	41.293,86
Cash and cash equivalents (Refer note 4)	5.004,15	41.293,86
Total cash and cash equivalents considered for cash flows	5.004,15	41.293,86

See accompanying notes to the Standalone financial statements 1-18

In terms of our report attached

For

Chartered Accountants


 Thomas Burmester
 Partner
Date : 16th June, 2021
Place : HamburgFor and on behalf of the Board of Directors of
Fermenta Biotech GmbH

 Viviane Spethmann-Berssenbrügge
 Managing Director
Date : 16th June, 2021
Place : Hamburg

1 Other Intangible assets

(` in EUR)

Particulars	Computer software	Product know -how	Total
At cost or deemed cost as at April 01, 2019	-	-	-
Additions	-	560.417,70	560.417,70
Balance as at March 31, 2020	-	560.417,70	560.417,70
Additions	23.185,00	-	23.185,00
Balance as at March 31, 2021	23.185,00	560.417,70	583.602,70
Accumulated amortisation			
As at April 01, 2019	-	-	-
Amortisation expense	-	-	-
Balance as at March 31, 2020	-	-	-
Amortisation expense	3.567,73	115.461,27	119.029,00
Balance as at March 31, 2021	3.567,73	115.461,27	119.029,00
Carrying amount			
As at March 31, 2020	-	560.417,70	560.417,70
Balance as at March 31, 2021	19.617,27	444.956,43	464.573,70

2 Inventories

	March 31, 2021	March 31, 2020
(At lower of cost and net realisable value)		
Raw materials and packing materials	1.459.402,12	1.256.305,16
Work-in-progress	-	-
Finished goods	1.935.617,15	790.368,67
Stores and spares	-	-
Total	3.395.019,00	2.046.673,83

3 Trade receivables (unsecured)

	March 31, 2021	March 31, 2020
Considered good	15.280,00	106.312,50
Credit Impaired	-	-
	15.280,00	106.312,50
Less : Allowance for doubtful debts (Expected credit loss allowance)	-	-
Total	15.280,00	106.312,50
Balance at the end of the year	-	-

4 Cash and cash equivalents

	March 31, 2021	March 31, 2020
Balances with banks		
In current accounts	5.004,15	41.293,86
Total	5.004,15	41.293,86

5 Other current assets

	March 31, 2021	March 31, 2020
Advance for supply of goods and services		
Considered good	132.750,40	-
Considered doubtful	-	-
Less: Allowance for doubtful advances	-	-
	132.750,40	-
Prepaid expenses	6.281,30	-
Balances with government authorities	4.210,51	1.293,66
Total	143.242,21	1.293,66



6	Equity share capital	(` in EUR)
	March 31, 2021	March 31, 2020
Authorised		
	25.000,00	25.000,00
	-	-
	25.000,00	25.000,00
Issued, subscribed and fully paid-up		
Fermenta Biotech Limited (25000 @ 1 EUR)		
	25.000,00	25.000,00
	-	-
	25.000,00	25.000,00

Notes to the Standalone financial statements for the year ended March 31, 2021

7 Other equity

(' in EUR)

	Reserves and Surplus							Items of other comprehensive income	Total
	Unrealised gain/(loss) on dilution	Capital redemption reserve	Capital reserve pursuant to amalgamation	Capital reserve	General reserve	Share options outstanding account	Retained earnings	Equity instruments through OCI	
Balance as at April 01, 2019	-	-	-	-	-	-	-	-	-
Profit for the year	-	-	-	-	-	-	(277.426,45)	-	(277.426,45)
Balance as at March 31, 2020	-	-	-	-	-	-	(277.426,45)	-	(277.426,45)
Profit for the year	-	-	-	-	-	-	(219.986,95)	-	(219.986,95)
Balance as at March 31, 2021	-	-	-	-	-	-	(497.413,40)	-	(497.413,40)

**8 Trade payables (Current)**

	March 31,2021	March 31,2020
Total outstanding dues of creditors	4.481.854,64	3.008.418,00
Total	4.481.854,64	3.008.418,00

9 Other Current Liability

	March 31,2021	March 31,2020
	-	-
Statutory Liabilities	13.677,88	-
Total	13.677,88	-

10 Revenue from operations

	March 31, 2021	March 31, 2020
Sale of products	245.910,00	106.312,50
Total	245.910,00	106.312,50

11 Other income

	March 31, 2021	March 31, 2020
Liabilities / provisions no longer required written back	184.621,88	-
Total	184.621,88	-

12 Cost of materials consumed

	March 31, 2021	March 31, 2020
Inventories of raw materials / packing materials at the beginning of the year	1.256.305,16	-
Add : Purchases	1.477.219,69	2.392.773,16
Less : Inventories of raw materials / packing materials at the end of the year	1.459.402,12	1.256.305,16
Total	1.274.122,73	1.136.468,00

13 Changes in inventories of finished goods, stock-in-trade and work-in-progress

	March 31, 2021	March 31, 2020
Inventories at the end of the year		
Work-in-progress	-	-
Finished goods	1.935.617,15	790.368,67
	<u>1.935.617,15</u>	<u>790.368,67</u>
Inventories at the beginning of the year		
Work-in-progress	-	-
Finished goods	790.368,67	-
	<u>790.368,67</u>	<u>-</u>
	(1.145.248,48)	(790.368,67)

14 Depreciation and amortisation expense

	March 31, 2021	March 31, 2020
Amortisation of intangible assets	119.029,00	-
Total	119.029,00	-

15 Other expenses

	March 31, 2021	March 31, 2020
Processing charges	144.118,03	11.836,30
Freight and forwarding charges	68.386,37	-
Insurance	3.643,90	-
Rates and taxes	2.639,10	87,50
Travelling and conveyance	97,76	-
Professional and legal fees	183.166,70	25.307,65
Foreign exchange loss (net)	-	159,00
Postage and telephone	64,30	-
Printing and stationery	-	80,00
Bank charges	404,42	169,17
Miscellaneous expenses	95,00	-
Total	402.615,58	37.639,62

16 Related parties disclosures

A) Names of the related parties where there are transactions and description of relationships

	Country of Incorporation	Proportion of ownership interest as at	
		March 31, 2021	March 31, 2020
a) Holding Company: Fermenta Biotech Limited	India	100%	100%
Subsidiaries: NA			

b) Key Management Personnel

Name of Key Management Personnel	Designation
i) Key Management Personnel Ms. Viviane Spethmann	Managing Director

(' in EUR)

B) Related party transactions:					(' in EUR)	
Sr.No.	Particulars	Holding Company	Subsidiaries	Key management personnel*	Enterprise significantly influenced by KMP or their relatives	Joint ventures / associates
1	Remuneration to Directors and Key Management Personnel (including commission)*	22.202,06 (12,000)	(-)		(-)	(-)
5	Expenditure incurred by related parties on behalf of Fermenta Biotech GmbH	23.184,87 (564.417,70)	(-)	(-)	(-)	(-)
7	Purchase of raw materials and packing materials					
	Fermenta Biotech Ltd.	1.041.715,24 (1.101.600,00)	- (-)	- (-)	- (0,00)	- (-)

C) Balance outstanding as at the end of the year :

(' in EUR)

	March 31, 2021	March 31, 2020
a. Trade payables and reimbursement payables		
Fermenta Biotech Ltd.	2,730,917,74	1,666,017,70

17 Commitments and Contingent liabilities

	March 31, 2021	March 31, 2020
(ii) Contingent liabilities:		
Claims against the company not acknowledged as debts		
Letter of Comfort Issued by Holding Company on behalf of Fermenta Biotech GmbH	350.000,00	350.000,00

18 Financial risk management objectives and policies

The Company is exposed to credit risk, liquidity risk and market risk. The Company's financial risk management is an integral part of how to plan and execute its business strategies. The Board of Directors review and agree policies for managing each of these risks, which are summarised below.

Market risk

Market risk is the risk of loss of future earnings, fair values or future cash flows that may result from adverse changes in market rates and prices (such as interest rates, foreign currency exchange rates, commodity prices and equity price risk). Market risk is attributable to all market risk-sensitive financial instruments, all foreign currency receivables and payables and all short term and long-term borrowings. The Company is exposed to market risks related to foreign exchange rate risk, commodity rate risk, interest rate risk and other price risks, such as equity price risks. Thus, the Company's exposure to market risk is a function of borrowing activities, revenue generating and operating activities in foreign currencies.

i) Commodity rate risk

Exposure to market risk with respect to commodity prices primarily arises from the Company's purchases and sales of active pharmaceutical ingredients, including the raw material components for such active pharmaceutical ingredients. The prices of the Company's raw materials generally are stable. Cost of raw materials forms the largest portion of the Company's cost of revenues. A large portion of the Company's sales are subject to commodity rate risk having a volatile pricing. The Company monitors overall demand supply position and pricing movement to decide marketing strategies to overcome risk of changing prices of the products.

ii) Foreign currency risk

The Company's foreign exchange risk arises from its foreign currency revenues and expenses and foreign currency borrowings. As a result, if the value of the Euro appreciates relative to these foreign currencies, the Company's revenues and expenses measured in Euro may decrease or increase and vice-versa. The exchange rate between the Euro and these foreign currencies have changed substantially in recent periods and may continue to fluctuate substantially in the future. Consequently, the Company largely uses the natural hedge to mitigate the risk of changes in foreign currency exchange rates in respect of its highly probable forecasted transactions and recognised assets and liabilities.

The Company did not enter into any derivative instruments for hedge or speculation. The year end foreign currency exposures that have not been hedged (before giving effects of natural hedge) by derivative instrument or otherwise are given below:

iii) Trade receivables

The Company has used expected credit loss (ECL) model for assessing the impairment loss. For this purpose, the Company uses a provision matrix to compute the expected credit loss amount. The provision matrix takes into account external and internal risk factors and historical data of credit losses from various customers. The Company evaluates the concentration of risk with respect to trade receivables which is low, as its customers are widely spread with small outstanding amounts (For detailed movement in provision for trade receivables - Refer note 3)

(' in EUR)

Trade receivables	March 31, 2021	March 31, 2020
Not due		
1 - 90 days		
91 -180 days		
Beyond 180 days	15.280,00	-
	15.280,00	-